Amgen UK’s Chris Fox: Up for the Challenge
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
Address: 1 Longwalk Road
Stockley Park
Uxbridge, UB11 1DB,United Kingdom
Tel: +44 (0) 208 831 8300
Web: http://www.celgene.co.uk/
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery and the development of products for the treatment of cancer and other severe, immune, inflammatory conditions.
Celgene Corporation and its employees are working relentlessly to provide solutions for unmet medical needs in cancer and debilitating inflammatory diseases.
There are more than 200 ongoing clinical trials at major medical centres worldwide using innovative compounds from Celgene. These investigational compounds are being actively studied in clinical trials for patients with incurable haematological and solid tumour cancers, including:
multiple myeloma
myelodysplastic syndromes
chronic lymphocytic leukaemia
non-Hodgkin’s lymphoma
glioblastoma
ovarian cancer
pancreatic cancer
prostate cancer
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of…
KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united…
Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure…
Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
See our Cookie Privacy Policy Here
